Natco Pharma has signed a nonexclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines. The medicines include sofosbuvir, ledipasvir/sofosbuvir and the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.
This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries. Under the license, Natco can set its own price for the generic products it produces, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
Natco Pharma is currently trading at Rs. 1410.05, up by 41.35points or 3.02% from its previous closing of Rs. 1368.70 on the BSE.
This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries. Under the license, Natco can set its own price for the generic products it produces, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
Natco Pharma is currently trading at Rs. 1410.05, up by 41.35points or 3.02% from its previous closing of Rs. 1368.70 on the BSE.
No comments:
Post a Comment